Figure 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

Figure 2 from A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies

<p>Mean plasma concentration vs. time profiles of subasumstat following intravenous infusions – phase I. <b>A,</b> C1D1. <b>B,</b> C1D8. Semi-logarithmic scale. Time points were relative to the start of subasumstat infusion.</p>

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkki: Dejan Juric (15126249) (author)
Eará dahkkit: Daniel Anderson (22644919) (author), Afshin Dowlati (15092092) (author), Jordi Rodon (15047721) (author), Iwona Lugowska (19135437) (author), Sławomir Mańdziuk (22644922) (author), Yuqin Song (15056930) (author), Feng Jung Sherida H. Woei-A-Jin (22644925) (author), Marc André (22644928) (author), Joanna Góra Tybor (22644931) (author), José-Ángel Hernández-Rivas (15050828) (author), Razelle Kurzrock (13559744) (author), Armando López-Guillermo (15028145) (author), David Schröder (22644934) (author), Rafal Stec (22644937) (author), Allison Berger (15134507) (author), Bo Chao (22644940) (author), Aleksander Chudnovsky (22644943) (author), John P. Gibbs (22644946) (author), Tao Long (22644949) (author), Dina Stroopinsky (16732851) (author), Qi Dong (22644952) (author), Anthony J. Olszanski (15031292) (author)
Almmustuhtton: 2025
Fáttát:
Cancer
Immuno-oncology
Clinical Research and Trials
Clinical Trial Results
Phase II clinical trials
Combination Immunotherapy
Immunology
Immune responses to cancer
Phase I Clinical Trials
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Geahča maid